

PRESS RELEASE

Advanced Proteome Therapeutics Corporation and WILEX subsidiary Heidelberg Pharma collaborate to create improved cancer therapeutics

- Companies will combine Heidelberg Pharma's proprietary Antibody Targeted Amanitin Conjugates (ATAC) technology with APC's proprietary site-specific protein modification technology

Munich, Germany / Vancouver, Canada, 14 June 2016 – WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) and the Advanced Proteome Therapeutics Corporation, (TSX:V APC) today announced that Heidelberg Pharma GmbH, a subsidiary of WILEX AG, entered into a partnership with the Canadian APC to create a new generation of antibody-drug conjugates (ADCs).

The companies will test combining APC's proprietary site-specific protein modification technology and Heidelberg Pharma's proprietary ATAC technology in order to generate a cancer therapeutic with enhanced characteristics that can also serve as a prototype for a new generation of antibody-drug conjugates (ADCs).

"We are delighted to work with APC on the next generation of cancer therapies using APC's approach which might broaden the scope of coupling methods for our ATAC technology", commented Andreas Pahl, CSO of WILEX AG and Heidelberg Pharma GmbH.

Allen Krantz, Founder and CEO of APC added: "The application of our site-specific technology to Heidelberg Pharma's novel payload has the potential to result in examples of more homogeneous and more effective ADCs than have been available to date, while giving rise to a new type of antibody-drug conjugate with substantial appeal to the industry."

Demonstrable success in the milestone-driven research, using a combination of both technologies, provides a basis for the companies to work towards taking an eligible therapeutic product candidate into clinical studies.

Heidelberg Pharma's aim and expertise is in making the compound Amanitin available as a new cancer therapy. Amanitin has a unique biological mode of action which could be used as the basis for developing highly effective, innovative drugs. Selective treatment of tumours using cytotoxic payloads like Amanitin via specific antibody-drug conjugates could enable much more effective therapy than existing drugs. Heidelberg Pharma is building a pipeline of ATAC product development candidates alone or with partners.

About WILEX and Heidelberg Pharma

WILEX AG is a biopharmaceutical company acting as a holding company and Group parent. Research and development focus on the operations of its subsidiary Heidelberg Pharma GmbH in Ladenburg, which primarily advances the development of the innovative platform technology for antibody-drug conjugates based on the use of Amanitin as a payload (ATAC technology) and provides pre-clinical drug discovery and development services. WILEX has a couple of diagnostic and therapeutic Phase III drug candidates which are available for out-licensing for external partners. WILEX is listed at the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information: www.wilex.com

About APC

Advanced Proteome Therapeutics Corporation (APC) is advancing a site-specific Protein Modification technology platform to enable the development of superior protein therapeutics. Using this technology, the Company has generated numerous and diverse modifications of annexin proteins with superior binding and stability properties which are amenable to further labeling and conjugation for use in therapeutic applications. APC is now vigorously applying its technologies to achieve the site-specific labeling of therapeutic antibodies and provide the next generation of antibody-drug conjugates. More information: www.advancedproteome.com

Company Contact

WILEX AG

Sylvia Wimmer
Tel.: +49 (0)89-41 31 38-29
Email: [investors\[at\]wilex.com](mailto:investors[at]wilex.com)
Grillparzerstr. 18, 81675 Munich, Germany

MC Services (IR/PR support)

Katja Arnold (CIRO)
Tel.: +49-89-210 228-40
Email: katja.arnold[at]mc-services.eu

Advanced Proteome Therapeutics Corp.

Alexander (Allen) Krantz
President and Chief Executive Officer
Tel: +1-617 638-0340

Heidelberg Pharma GmbH

Business Development
Dr. Marcel Linssen
CBO, Executive Vice President
Tel.: +49-6203-1009-40
Email: [m.linssen\[at\]hdpharma.com](mailto:m.linssen[at]hdpharma.com)

Scott Young
Investor Relations
Tel: +1-705 888-2756

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.